by Richard Daverman, PhD
November 14, 2012 -- To increase China sales of its biologic drugs, Roche is using a strategy that works in the west: insurance. The company is working with Swiss Re to offer insurance at a nominal amount to China’s residents. Although China offers a basic level of insurance to its citizens, the plans do not cover Roche’s high-priced cancer drugs. So far, according to a Bloomberg article, six million Chinese have signed up, and ten million are expected before the end of the year. More details....
Stock Symbol: (VX: ROG)
